EVGN News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

EV

Mkt Cap

$6.2M

Volume

37.45K

Next Earnings

November 19th

Loading chart

EV

EVGNEVOGENE LTD.

EVGN

Pay with—

Available Balance0.00

EV

Mkt Cap

$6.1M

Volume

37.45K

Next Earnings

November 19th

Chart Financials Earnings News About Insider Filings

Plant Genotyping Equipment Market Size to Hit 1662.43 - GlobeNewswireThe plant genotyping equipment market is experiencing significant growth due to advancements in sequencing technologies and increasing demand for high-yield, stress-tolerant crops. The market is expected to reach $1662.43 million by 2032, driven by the need for efficient, high-yield crop production methods.GlobeNewswire Inc. · Jul 19, 2024

Global Agricultural Biotechnology Market Size To Worth USD 268.32 Billion By 2033 | CAGR of 8.27% - GlobeNewswireThe global agricultural biotechnology market is expected to grow from USD 121.24 billion in 2023 to USD 268.32 billion by 2033, driven by increasing demand for sustainable agriculture and food security.GlobeNewswire Inc. · Jul 18, 2024

Evogene (EVGN) Reports Q4 Loss, Misses Revenue EstimatesEvogene (EVGN) delivered earnings and revenue surprises of 7.14% and 66.59%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · Mar 7, 2024

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue EstimatesMirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of -94.12% and 4.23%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · Feb 28, 2024

Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue EstimatesFate Therapeutics (FATE) delivered earnings and revenue surprises of 21.05% and 97.18%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · Feb 26, 2024

Here's Why Evogene (EVGN) is a Great Momentum Stock to BuyDoes Evogene (EVGN) have what it takes to be a top stock pick for momentum investors? Let's find out.Zacks Investment Research · Jan 12, 2024

Is Compugen (CGEN) Outperforming Other Medical Stocks This Year?Here is how Compugen (CGEN) and Evogene (EVGN) have performed compared to their sector so far this year.Zacks Investment Research · Dec 5, 2023

Bears are Losing Control Over Evogene (EVGN), Here's Why It's a 'Buy' NowAfter losing some value lately, a hammer chart pattern has been formed for Evogene (EVGN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.Zacks Investment Research · Nov 29, 2023

Benzinga's Top Ratings Upgrades, Downgrades For October 2, 2023Upgrades For Invitation Homes Inc (NYSE:INVH), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. For the second quarter, Invitation Homes had an EPS of $0.44, compared to year-ago quarter EPS of $0.42. The stock has a 52-week-high of $36.53 and a 52-week-low of $28.52. At the end of the last trading period, Invitation Homes closed at $31.69. For Xylem Inc (NYSE:XYL), Melius Research upgraded the previous rating of Hold to Buy. In the second quarter, Xylem showed an EPS of $0.98, compared to $0.66 from the year-ago quarter. The current stock performance of Xylem shows a 52-week-high of $118.58 and a 52-week-low of $84.16. Moreover, at the end of the last trading period, the closing price was at $91.03. According to DA Davidson, the prior rating for Clorox Co (NYSE:CLX) was changed from Neutral to Buy. In the fourth quarter, Clorox showed an EPS of $1.67, compared to $0.93 from the year-ago quarter. At the moment, the stock has a 52-week-high of $178.21 and a 52-week-low of $124.59. Clorox closed at $131.06 at the end of the last trading period. BTIG upgraded the previous rating for LGI Homes Inc (NASDAQ:LGIH) from Sell to Neutral. For the second quarter, LGI Homes had an EPS of $2.25, compared to year-ago quarter EPS of $5.20. The stock has a 52-week-high of $141.91 and a 52-week-low of $74.61. At the end of the last trading period, LGI Homes closed at $99.49. Morgan Stanley upgraded the previous rating for United States Steel Corp (NYSE:X) from Equal-Weight to Overweight. In the second quarter, United States Steel showed an EPS of $1.92, compared to $3.86 from the year-ago quarter. The current stock performance of United States Steel shows a 52-week-high of $32.68 and a 52-week-low of $18.02. Moreover, at the end of the last trading period, the closing price was at $32.48. According to Susquehanna, the prior rating for FedEx Corp (NYSE:FDX) was changed from Neutral to Positive. In the first quarter, FedEx showed an EPS of $4.55, compared to $3.44 from the year-ago quarter. The stock has a 52-week-high of $270.95 and a 52-week-low of $147.33. At the end of the last trading period, FedEx closed at $264.92. For Rivian Automotive Inc (NASDAQ:RIVN), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. Rivian Automotive earned $1.08 in the second quarter, compared to $1.62 in the year-ago quarter. The current stock performance of Rivian Automotive shows a 52-week-high of $37.38 and a 52-week-low of $11.68. Moreover, at the end of the last trading period, the closing price was at $24.28. According to Piper Sandler, the prior rating for Zscaler Inc (NASDAQ:ZS) was changed from Neutral to Overweight. Zscaler earned $0.64 in the fourth quarter, compared to $0.25 in the year-ago quarter. The stock has a 52-week-high of $185.90 and a 52-week-low of $84.93. At the end of the last trading period, Zscaler closed at $155.59. For Datadog Inc (NASDAQ:DDOG), Piper Sandler upgraded the previous rating of Neutral to Overweight. Datadog earned $0.36 in the second quarter, compared to $0.24 in the year-ago quarter. The stock has a 52-week-high of $118.02 and a 52-week-low of $61.34. At the end of the last trading period, Datadog closed at $91.09. According to Piper Sandler, the prior rating for Macerich Co (NYSE:MAC) was changed from Underweight to Neutral. For the second quarter, Macerich had an EPS of $0.40, compared to year-ago quarter EPS of $0.46. The stock has a 52-week-high of $14.51 and a 52-week-low of $7.73. At the end of the last trading period, Macerich closed at $10.91. According to Jefferies, the prior rating for Insulet Corp (NASDAQ:PODD) was changed from Hold to Buy. Insulet earned $0.38 in the second quarter, compared to $0.06 in the year-ago quarter. At the moment, the stock has a 52-week-high of $335.91 and a 52-week-low of $152.43. Insulet closed at $159.49 at the end of the last trading period. For Mr. Cooper Group Inc (NASDAQ:COOP), Keefe, Bruyette & Woods upgraded the previous rating of Market Perform to Outperform. For the second quarter, Mr. Cooper Gr had an EPS of $1.66, compared to year-ago quarter EPS of $0.17. The current stock performance of Mr. Cooper Gr shows a 52-week-high of $60.68 and a 52-week-low of $37.54. Moreover, at the end of the last trading period, the closing price was at $53.56. According to Keefe, Bruyette & Woods, the prior rating for PennyMac Financial Services Inc (NYSE:PFSI) was changed from Market Perform to Outperform. PennyMac Financial Servs earned $1.11 in the second quarter, compared to $2.28 in the year-ago quarter. The current stock performance ...Full story available on Benzinga.comBenzinga · Oct 2, 2023

Evogene (EVGN) Could Find a Support Soon, Here's Why You Should Buy the Stock NowEvogene (EVGN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.Zacks Investment Research · Aug 21, 2023

to start trading

EV

EVGNEVOGENE LTD.

EVGN

Pay with—

Available Balance0.00

Your PositionYou don't own any EVGN yet.

Related Tickers

Earnings